This CPB has been revised to: (i) add "intolerance or contraindication to methotrexate or leflunomide (see Appendix), or another conventional synthetic drug (e.g., sulfasalazine)" to the initial criteria for mild to moderate psoriatic arthritis, and (ii) add appendix for examples of contraindications to methotrexate or leflunomide.